Increased Uptake Of Currently-Available Therapies Will Drive Modest $400 Million Growth In The Parkinson's Disease Drug Market From 2009 To 2019

Main Category: Parkinson's Disease
Also Included In: Pharma Industry / Biotech Industry
Article Date: 13 Sep 2010 - 2:00 PDT


Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, although increased uptake of currently-available therapies will drive modest $400 million growth in the Parkinson's disease drug market through 2019, generic erosion of key agents will constrain overall market growth in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

The Pharmacor 2010 findings from the topic entitled Parkinson's Disease reveal that the majority of sales will continue to be fueled by the leading dopamine agonists, driving the market from $2.6 billion in 2009 to $3 billion in 2019. The leading agents in this class include pramipexole (Boehringer Ingelheim's Mirapex/Mirapexin/Sifrol/BI-Sifrol, generics; Mirapex ER/Mirapexin ER/Sifrol Retard) and ropinirole (GlaxoSmithKline's Requip, generics; GlaxoSmithKline/SkyePharma's Requip XL/LP/RP/Modutab/Prolib).

Another key driver of growth in the Parkinson's disease drug market will be the increased uptake of Teva Pharmaceuticals/Lundbeck's Azilect/Agilect (rasagiline) in the United States and Europe through 2019 and the launch of this agent in Japan in 2015. Increased use of Azilect/Agilect, a monoamine oxidase B inhibitor, will be driven by clinical data supporting its use in early Parkinson's disease as a disease-modifying agent.

However, overall market growth will be constrained by the increased uptake of generic versions of immediate- and extended-release formulations of pramipexole as well as immediate- and controlled-release formulations of ropinirole. Additionally, Agilect/Azilect and Novartis/Orion Pharma's Comtan/Comtess/Stalevo (entacapone) will also lose patent exclusivity over the next decade.

"By 2019, the genericization of several key Parkinson's disease therapies will create a fragmented market with no clear leader, as a large number of similarly priced drugs compete for the same patient share," said Decision Resources Analyst Sami Fam, Ph.D. "Future therapies in this indication will need to clearly differentiate themselves from other therapies to gain a competitive edge in this mature market."

Source: Decision Resources

• Additional
• References
• Citations